BCL2 and acute myeloid leukemia: Our results indicated that ME1high cells were more resistant to standard AML chemotherapeutic agents such as cytarabine and daunorubicin, as well as to Bcl-2 family inhibitors (obatoclax and venetoclax) (Figure 6A).